Harmonising access and reinventing the procurement of innovative medicines in Europe
Europe pays for innovative medicines through 27 uncoordinated national negotiations, generating access delays, cross-country pricing externalities, and a weak position vis-à-vis both pharmaceutical firms and
US tariffs may deepen integration, elsewhere
While recent analysis has focused on direct impacts of US tariffs and potential retaliation, major US trading partners have intensified trade negotiations with each other,
